Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.

Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.

There is clearly a necessity to identify novel non-dopaminergic mechanisms as new therapeutic targets for Parkinson's disease (PD). Among these, the soluble guanylyl cyclase (sGC)-cGMP signaling cascade is emerging as a promising candidate for second messenger-based therapies for the ameliorati...

Full description

Bibliographic Details
Main Authors: Kuei Y Tseng, Adriana Caballero, Alexander Dec, Daryn K Cass, Natalie Simak, Elizabeth Sunu, Michael J Park, Shannon R Blume, Stephen Sammut, Diana J Park, Anthony R West
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3206945?pdf=render

Internet

http://europepmc.org/articles/PMC3206945?pdf=render

Similar Items